No Negative Psychological Impact Seen for Disclosing Aβ Status
By Elana Gotkine HealthDay Reporter
FRIDAY, May 9, 2025 -- Disclosure of amyloid-β (Aβ) status seems not have a negative psychological impact, according to a study published online May 7 in Alzheimer's & Dementia.
Sapir Golan Shekhtman, from Sheba Medical Center in Ramat Gan, Israel, and colleagues examined emotional responses to Aβ status disclosure in cognitively normal individuals. To assess anxiety and depression associated with an elevated result, subjective memory complaints, and motivation for risk-reduction behavior, questionnaires were administered before and six months after disclosure of Aβ positron emission tomography (PET) results. Data were included for 199 cognitively normal adults.
The researchers observed reductions in all emotional parameters in association with nonelevated Aβ status disclosure relative to baseline. No changes in depression or memory complaints were seen in association with elevated Aβ disclosure, while there was a modest decrease in anxiety and motivation to change lifestyle.
"Our findings suggest no psychological harm in elevated and nonelevated Aβ PET scan status disclosure, strengthening findings from previous studies," the authors write. "The decrease in motivation to implement lifestyle changes after the disclosure of elevated or nonelevated Aβ status warns against false reassurance during the disclosure process."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Adding Anxiety as Qualifier for Medical Cannabis Increases Number of Certifications
FRIDAY, July 11, 2025 -- Adding anxiety disorders as a qualifying condition for medical cannabis in Pennsylvania was associated with an increase in certifications, according to a...
Gabapentin for Back Pain Linked to Increased Risk for Dementia, MCI
FRIDAY, July 11, 2025 -- For adults with chronic low back pain, gabapentin prescription is associated with an increased risk for dementia and mild cognitive impairment (MCI)...
Lead Exposure Linked to Faster Rate of Forgetting Among Children
FRIDAY, July 11, 2025 -- Developmental lead (Pb) exposure is associated with an increased rate of forgetting among children, according to a study published online July 9 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.